A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas

Trial Profile

A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs TRC 102 (Primary) ; Temozolomide
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Lymphoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Results (n=15) from the expansion phase of the trial, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 03 Sep 2016 Planned End Date changed from 1 Feb 2017 to 1 Dec 2019.
    • 03 Sep 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top